When asked to define adjuvant HF treatment in AiCM (multiple choice), the majority included drug treatment with betablockers—(193, 94%) and/or mineralocorticoid receptor antagonists—(167, 81%), sodium glucose transport protein 2 (SGLT2) antagonists—(161, 78%), angiotensin receptor–neprilysin inhibitor—(158, 77%), and angiotensin converting enzyme inhibitors or receptor blockers—(142, 69%, Figure 3). This evidence concerns the gene ACE and hydrops fetalis.